Ironwood Pharmaceuticals (NASDAQ:IRWD) announced its quarterly earnings data on Thursday, February 15th. The biotechnology company reported ($0.14) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.04, Bloomberg Earnings reports. Ironwood Pharmaceuticals had a negative return on equity of 2,458.64% and a negative net margin of 39.20%. The business had revenue of $94.20 million for the quarter, compared to the consensus estimate of $88.86 million. During the same period in the previous year, the business earned ($0.12) earnings per share. The business’s revenue was up 7.7% on a year-over-year basis.
Ironwood Pharmaceuticals (NASDAQ:IRWD) traded up $0.28 during midday trading on Friday, hitting $14.83. The company had a trading volume of 1,045,400 shares, compared to its average volume of 1,801,962. The company has a debt-to-equity ratio of -22.31, a quick ratio of 4.86 and a current ratio of 4.87. Ironwood Pharmaceuticals has a 52-week low of $12.89 and a 52-week high of $19.94.
In other Ironwood Pharmaceuticals news, insider Mark G. Currie sold 60,000 shares of the stock in a transaction dated Wednesday, January 24th. The stock was sold at an average price of $15.45, for a total transaction of $927,000.00. Following the sale, the insider now directly owns 835,000 shares of the company’s stock, valued at approximately $12,900,750. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Gina Consylman sold 3,594 shares of the stock in a transaction dated Wednesday, February 21st. The stock was sold at an average price of $14.66, for a total transaction of $52,688.04. Following the sale, the chief financial officer now directly owns 59,125 shares in the company, valued at $866,772.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 180,133 shares of company stock worth $2,743,001. 7.63% of the stock is owned by insiders.
Several equities research analysts have recently issued reports on IRWD shares. ValuEngine raised Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, November 29th. BidaskClub cut Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, December 30th. Bank of America cut Ironwood Pharmaceuticals from a “buy” rating to an “underperform” rating and reduced their price objective for the stock from $20.00 to $15.00 in a research note on Friday, January 5th. Morgan Stanley restated a “hold” rating on shares of Ironwood Pharmaceuticals in a research report on Monday, December 4th. Finally, Zacks Investment Research upgraded Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, January 18th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $17.75.
TRADEMARK VIOLATION WARNING: This news story was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://stocknewstimes.com/2018/02/23/ironwood-pharmaceuticals-irwd-posts-earnings-results-beats-expectations-by-0-04-eps.html.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.